Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AQW051 proof-of-concept trial in mild Alzheimer's disease and amnestic mild cognitive impairment
2007-001846-42Phase 2Terminated
- Sponsor
- Novartis
- Start
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of AQW051 in Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI) (4 arms), sponsored by Novartis. Primary endpoint: Primary pharmacodynamic/efficacy assessments. Started Jun 2007; status: terminated.
02
Drugs
AQW051
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on 2007-001846-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001846-42.